Description
Release form
tablets
Packing
30 pcs.
Pharmacological action
Venlaxor has an antidepressant effect.
Indications
Depression of various etiologies (treatment and prevention).
Contraindications
hypersensitivity
simultaneous administration of MAO inhibitors
severe impaired renal and / or liver function (glomerular filtration rate (GFR)
age under 18 years (safety and efficacy for this age group not proven)
established or suspected pregnancy
Special instructions
Cancellation of Venlaxor: As with other antidepressants, abrupt discontinuation of venlafaxine therapy – especially after high doses of the drug – can cause withdrawal symptoms, and therefore it is recommended to gradually reduce its dose before discontinuing the drug.
The duration of the period required to reduce the dose depends on the dose, the duration of therapy, as well as the individual sensitivity of the patient.
Composition of
1 tablet contains venlafaxine (as hydrochloride) 75 mg
Dosage and Administration
Inside, with meals. The recommended initial dose of Venlaxor is 75 mg in 2 divided doses (37.5 mg each) daily.
Side effects
Common symptoms: weakness, increased fatigue.
From the gastrointestinal tract: decreased appetite, constipation, nausea, vomiting, dry mouth rarely – hepatitis.
From the side of metabolism: increased serum cholesterol, decreased body weight, sometimes – a change in laboratory tests of liver function, hyponatremia, syndrome of insufficient secretion of antidiuretic hormone.
From the cardiovascular system: arterial hypertension, sometimes – postural hypotension, tachycardia.
From the nervous system: unusual dreams, dizziness, insomnia, increased irritability, paresthesia, stupor, increased muscle tone, tremors, yawning sometimes – apathy, hallucinations, muscle cramps, serotonin syndrome rarely – epileptic seizures, manic reactions, as well as symptoms, resembling malignant antipsychotic syndrome.
From the genitourinary system: disturbances in ejaculation, erection, anorgasmia, dysuric disorders (mainly difficulties at the beginning of urination), sometimes – decreased libido, menorrhagia, urinary retention.
On the part of the sensory organs: disturbances of accommodation, mydriasis, visual impairment sometimes – a violation of taste sensations.
From the skin: hyperemia of the skin sweating sometimes – photosensitivity reactions rarely – erythema multiforme, Stevens-Johnson syndrome.
From the blood and hemopoietic system: sometimes – hemorrhages in the skin (ecchymosis) and mucous membranes, thrombocytopenia rarely – prolongation of bleeding time.
Overdose
Symptoms: ECG changes (lengthening of the QT interval, blockade of the bundle branch block, expansion of the QRS complex), sinus or ventricular tachycardia, bradycardia, hypotension, convulsive states, changes in consciousness (decrease in wakefulness). With an overdose of venlafaxine while taking it with alcohol and / or other psychotropic drugs, death has been reported.
Treatment: Activated charcoal is prescribed to reduce the absorption of the drug. It is not recommended to induce vomiting due to the risk of aspiration. Symptomatic therapy is performed. Specific antidotes are unknown. Continuous monitoring of vital functions (respiration and blood circulation) is recommended. Venlafaxine and its metabolite EFA are not excreted during dialysis.
Storage Conditions
Store the product in a dry, protected from light at a temperature not exceeding 25 ° C.
The Expiration of
is 3 years.
conditions granted through pharmacies
In retseptu
lekarstvennaja tablet form
Grindeks, Latvia
